Repeated intraperitoneal administration of the GABABreceptor agonist baclofen reduces body weight in the mouse

preprint OA: closed
📄 Open PDF Full text JSON View at publisher

Abstract

Chronic intraperitoneal (ip) administration of the GABA B receptor agonist baclofen has been shown to reduce body weight in rats without significantly affecting daily food intake. The present study was undertaken to extend these observations to another rodent species. Male C57B/10 mice (n=27) that had free access to food and water were injected once daily for 15 days with either saline or baclofen (4 or 8 mg / kg; i.p). Body weight and food intake were measured 24h after each injection. Statistical analysis of the results revealed that the 4 mg / kg dose of baclofen significantly reduced body weight gain in the mice during the first 5 days while the 8 mg / kg dose reduced body weight gain throughout the 15 days of the study when compared with saline control animals (F( 2,21 )=4.88, P<0.02). Baclofen (4 or 8 mg / kg) generally had no significant effects on daily 24h food intake except on days 1 and 2 when the 8 mg / kg dose produced small but significant decreases in food intake (P<0.05) that were probably due to the initial depressant effects of the drug on behaviour. The results of this study extend previous findings in rat to another rodent species and show that systemic administration of the GABA B receptor agonist baclofen reduces body weight gain in the mouse without affecting daily food intake. These results lend further support to the hypothesis that GABA B receptor agonists decreases body weight by increasing metabolic rate.
Full text 1,538 characters · extracted from oa-doi-fallback · click to expand
Abstract Chronic intraperitoneal (ip) administration of the GABAB receptor agonist baclofen has been shown to reduce body weight in rats without significantly affecting daily food intake. The present study was undertaken to extend these observations to another rodent species. Male C57B/10 mice (n=27) that had free access to food and water were injected once daily for 15 days with either saline or baclofen (4 or 8 mg / kg; i.p). Body weight and food intake were measured 24h after each injection. Statistical analysis of the results revealed that the 4 mg / kg dose of baclofen significantly reduced body weight gain in the mice during the first 5 days while the 8 mg / kg dose reduced body weight gain throughout the 15 days of the study when compared with saline control animals (F(2,21)=4.88, P<0.02). Baclofen (4 or 8 mg / kg) generally had no significant effects on daily 24h food intake except on days 1 and 2 when the 8 mg / kg dose produced small but significant decreases in food intake (P<0.05) that were probably due to the initial depressant effects of the drug on behaviour. The results of this study extend previous findings in rat to another rodent species and show that systemic administration of the GABAB receptor agonist baclofen reduces body weight gain in the mouse without affecting daily food intake. These results lend further support to the hypothesis that GABAB receptor agonists decreases body weight by increasing metabolic rate. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00